Clinical guideline
Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
J Natl Compr Canc Netw · 2026
Studies and guidelines: Pancreatic cancer
29 items with a structured summary · Pancreatic cancer: the complete guide
Clinical guideline
ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer
ESMO Open · 2025
Clinical guideline
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Ann Oncol · 2023
Clinical guideline
Metastatic Pancreatic Cancer: ASCO Guideline Update
J Clin Oncol · 2020
Clinical guideline
Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion
JCO · 2019
Clinical guideline
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021
Clinical trial · Phase 3
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
N Engl J Med · 2026
13.2 vs 6.6 monthsMedian overall survival (RAS G12)
Review article
Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma
DD&T · 2026
13.2 vs 6.7 monthsMedian overall survival (whole randomised population)
Clinical trial · Phase 3
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
Lancet Oncol · 2025
21.9 months vs 21.3 monthsMedian overall survival
Clinical trial · Phase 2
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
Lancet Gastroenterol Hepatol · 2024
60% vs 73%18-month survival (intention to treat)
Clinical trial · Phase 3
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
JAMA Oncol · 2022
21.4 months vs 12.8 monthsMedian disease-free survival
Clinical trial · Phase 3
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
J Clin Oncol · 2022
HR 0.73Overall survival (hazard ratio)
Clinical trial · Phase 3
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
J Clin Oncol · 2022
19.0 months vs 19.2 monthsMedian overall survival
Review article
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors
Nat Rev Gastroenterol Hepatol · 2021
More than doubled over the past 25 yearsGlobal burden of pancreatic cancer
Clinical trial · Phase 3
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
N Engl J Med · 2019
7.4 vs 3.8 monthsMedian progression-free survival
Observational study
Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes
Gastroenterology · 2018
0.87AUC for identifying patients who developed pancreatic cancer within 3 years of diabetes onset (exploratory cohort)
Clinical trial · Phase 3
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
Lancet · 2017
28.0 vs 25.5 monthsMedian overall survival
Observational study
Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer
Gut · 2015
498 of 2034 patients (24%)Proportion of patients in the EUS-FNA group
Clinical trial · Phase 3
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
N Engl J Med · 2013
8.5 vs 6.7 monthsMedian overall survival
Observational study
Risk of gastric or peritoneal recurrence, and long-term outcomes, following pancreatic cancer resection with preoperative endosonographically guided fine needle aspiration
Endoscopy · 2013
6 patients (15.4%) in the no-EUS-FNA group vs 13 patients (7.7%) in the EUS-FNA groupGastric or peritoneal recurrence (19 patients)
Clinical trial · Phase 2/3
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
N Engl J Med · 2011
11.1 vs 6.8 monthsMedian overall survival
Clinical trial
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
JCO · 1997
23.8% vs 4.8% (gemcitabine vs 5-FU)Clinical benefit response
Other
An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval
Nat Rev Clin Oncol · 2026
Clinical trial · Phase 1-2
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
N Engl J Med · 2026
35%Objective response (RAS G12, second line, 300 mg; 26 patients)
Other
The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026
J Hematol Oncol · 2026
13.2 vs 6.6 monthsMedian overall survival (daraxonrasib vs chemotherapy, second line)
Clinical trial · Phase 1
RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer
Nature · 2025
Not reached vs 13.4 monthsMedian recurrence-free survival: responders versus non-responders
Clinical trial · Phase 3
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Lancet · 2023
11.1 vs 9.2 monthsMedian overall survival
Clinical trial · Phase 1
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Nature · 2023
8 of 16 patientsInduction of neoantigen-specific T cells
Clinical trial · Phase 3
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
N Engl J Med · 2018
21.6 vs 12.8 monthsMedian disease-free survival
Nothing found.